{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:08:29Z","timestamp":1789088909795,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dadr.2026.100471","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:32:39Z","timestamp":1787153559000},"page":"100471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discontinuing extended-release buprenorphine: Participant experiences from a mixed-methods observational study"],"prefix":"10.1016","volume":"20","author":[{"given":"Marc","family":"Fishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwen","family":"Podesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"DeVeaugh-Geiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Le Moigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2S 1","key":"10.1016\/j.dadr.2026.100471_bib1","first-page":"1","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update","volume":"14","author":"American Society of Addiction Medicine","year":"2020","journal-title":"J. Addict. Med."},{"issue":"9","key":"10.1016\/j.dadr.2026.100471_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.dadr.2026.100471_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drugalcdep.2015.02.033","article-title":"Characterizing opioid withdrawal during double-blind buprenorphine detoxification","volume":"151","author":"Dunn","year":"2015","journal-title":"Drug. Alcohol. Depend."},{"issue":"4","key":"10.1016\/j.dadr.2026.100471_bib4","first-page":"765","article-title":"Buprenorphine enhanced taper tolerability evaluation report (BETTER): a case series","volume":"45","author":"Epland","year":"2024","journal-title":"Subst. Use Addctn J."},{"key":"10.1016\/j.dadr.2026.100471_bib5","doi-asserted-by":"crossref","DOI":"10.2196\/71245","article-title":"Social listening for patient experiences with stopping extended-release buprenorphine: content analysis of Reddit messages","volume":"27","author":"Gilbert","year":"2025","journal-title":"J. Med. Internet Res."},{"issue":"1","key":"10.1016\/j.dadr.2026.100471_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/add.15998","article-title":"The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment","volume":"118","author":"Glanz","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2026.100471_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug. Alcohol. Depend."},{"key":"10.1016\/j.dadr.2026.100471_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108447","article-title":"Naturalistic follow-up after a trial of medications for opioid use disorder: medication status, opioid use, and relapse","volume":"131","author":"Greiner","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"4","key":"10.1016\/j.dadr.2026.100471_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/00952990.2022.2065638","article-title":"Long-term patient outcomes following buprenorphine\/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population","volume":"48","author":"Hasan","year":"2022","journal-title":"Am. J. Drug. Alcohol. Abus."},{"key":"10.1016\/j.dadr.2026.100471_bib10","article-title":"Characterizing withdrawal from long-acting injectable buprenorphine: an observational case series","volume":"15","author":"Hayes","year":"2025","journal-title":"Drug. Alcohol. Depend. Rep."},{"issue":"4","key":"10.1016\/j.dadr.2026.100471_bib11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/add.70211","article-title":"Evaluating the optimal duration of medication treatment for opioid use disorder","volume":"121","author":"Hayes","year":"2026","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2026.100471_bib12","article-title":"Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms","volume":"15","author":"Horowitz","year":"2025","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.dadr.2026.100471_bib13","unstructured":"Indivior Inc (2026). Sublocade (buprenorphine extended-release) injection, for subcutaneous use [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/209819s037lbl.pdf"},{"issue":"4","key":"10.1016\/j.dadr.2026.100471_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","article-title":"Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials","volume":"60","author":"Jones","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"10118","key":"10.1016\/j.dadr.2026.100471_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dadr.2026.100471_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","article-title":"Buprenorphine tapering schedule and illicit opioid use","volume":"104","author":"Ling","year":"2009","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.dadr.2026.100471_bib17","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study","volume":"14","author":"Ling","year":"2020","journal-title":"J. Addict. Med."},{"issue":"8","key":"10.1016\/j.dadr.2026.100471_bib18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.dadr.2026.100471_bib19","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00213-023-06370-2","article-title":"Opioid withdrawal: role in addiction and neural mechanisms","volume":"240","author":"Monroe","year":"2023","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.dadr.2026.100471_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug. Alcohol. Depend."},{"issue":"3","key":"10.1016\/j.dadr.2026.100471_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/ADM.0000000000000738","article-title":"Using extended release buprenorphine injection to discontinue sublingual buprenorphine: a case series","volume":"15","author":"Ritvo","year":"2021","journal-title":"J. Addict. Med."},{"issue":"3","key":"10.1016\/j.dadr.2026.100471_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ajad.13414","article-title":"Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine","volume":"32","author":"Rodriguez","year":"2023","journal-title":"Am. J. Addict."},{"issue":"12","key":"10.1016\/j.dadr.2026.100471_bib23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamapsychiatry.2013.2216","article-title":"A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers","volume":"70","author":"Sigmon","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2026.100471_bib24","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.dadr.2026.100471_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drugalcdep.2018.05.010","article-title":"Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program","volume":"189","author":"Weinstein","year":"2018","journal-title":"Drug. Alcohol. Depend."},{"issue":"2","key":"10.1016\/j.dadr.2026.100471_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.dadr.2026.100471_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2010.08.001","article-title":"\"Should I stay or should I go?\" Coming off methadone and buprenorphine treatment","volume":"22","author":"Winstock","year":"2011","journal-title":"Int. J. Drug. Policy"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:21:44Z","timestamp":1789086104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724626000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S2772724626000648"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100471","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuing extended-release buprenorphine: Participant experiences from a mixed-methods observational study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100471"}}